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Alzheimer’s disease (AD) and vascular dementia are responsible for up to 90% of dementia
cases. According to the World Health Organization (WHO), a staggering number of 35.6
million people are currently diagnosed with dementia. Blocking disease progression or
preventing AD altogether is desirable for both social and economic reasons and recently
focus has shifted to a new and promising drug: the β-secretase inhibitor. Much of AD
research has investigated the amyloid cascade hypothesis, which postulates that AD is
caused by changes in amyloid beta (Aβ) stability and aggregation. Blocking Aβ production
by inhibiting the first protease required for its generation, β-secretase/BACE1, may be the
next step in blocking AD progression. In April 2012, promising phase I data on inhibitor
MK-8931 was presented. This drug reduced Aβ cerebral spinal fluids (CSF) levels up to
92% and was well tolerated by patients. In March 2013 data was added from a one week
trial in 32 mild to moderate AD patients, showing CSF Aβ levels decreased up to 84%.
However, β-site APP cleaving enzyme 1 (BACE1) inhibitors require further research. First,
greatly reducing Aβ levels through BACE1 inhibition may have harmful side effects. Second,
BACE1 inhibitors have yet to pass clinical trial phase II/III and no data on possible side
effects on AD patients are available. And third, there remains doubt about the clinical
efficacy of BACE1 inhibitors. In moderate AD patients, Aβ plaques have already been
formed. BACE1 inhibitors prevent production of new Aβ plaques, but hypothetically do not
influence already existing Aβ peptides. Therefore, BACE1 inhibitors are potentially better
at preventing AD instead of having therapeutic use.
Keywords: Alzheimer’s disease, amyloid cascade hypothesis, APP, amyloid-β, β-secretase, β-secretase inhibitors,
BACE1, drug
INTRODUCTION
Dementia is a collective name for progressive degenerative brain
syndromes which alter memory, behavior, thinking and emotion
(WHO, 2012). Several conditions are capable of causing dementia
symptoms, as a result of pathological changes in the brain due to
the loss of neurons. The most prevalent condition is Alzheimer’s
disease (AD); together with vascular dementia, it is responsible
for up to 90% of dementia cases (WHO, 2012). According to the
WHO, a staggering number of 35.6 million people were diagnosed
with dementia worldwide in 2010, and this number is projected to
nearly double every 20 years (WHO, 2012). Besides patients, their
families and caregivers are also affected. In 2010, the total world-
wide costs of dementia were estimated at $604 billion (Wilmo
and Martin, 2010). Therefore, blocking disease progression or
preventing dementia, and more specifically AD, is desirable for
both social and economic reasons. Current therapies, however, are
only capable of temporarily slowing down the cognitive decline of
AD (Cole and Vassar, 2007). Moreover, successful treatments that
address the underlying pathologic mechanisms of AD are lacking
(Cole and Vassar, 2007).
This review discusses the development of a high poten-
tial therapeutic drug in the battle against AD: the β-secretase
inhibitors. The role of β-secretase in the development of AD, the
working mechanism of β-secretase inhibitors in general and the
potential hurdles in the development of inhibitory drugs will be
presented.
EVIDENCE FOR THE AMYLOID CASCADE HYPOTHESIS
Much of AD research has been focused on the amyloid cascade
hypothesis, which was first established by Selkoe and his research
group in 1991 (Selkoe, 1991). It postulates that AD is caused by
changes in Aβ stability and aggregation or altered amyloid pre-
cursor protein (APP) expression, resulting in a chronic imbalance
between Aβ production and clearance. Accumulation of aggre-
gated Aβ initiates a cascade that includes inflammatory changes,
formation of neurofibrillary tangles and neurotransmitter loss
(Citron, 2004; Golde et al., 2006). This cascade is visualized in
Figure 1. Blocking the production of Aβ by inhibiting the first
proteases required for its generation, β-secretase, may prove to be
the next step in blocking AD progression or even preventing the
disease.
Several genes, involved in increasing Aβ production or depo-
sitioning, have also been implicated in the etiology of AD. These
genes include APP, the precursor of Aβ, PSEN1/PSEN2, that code
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FIGURE 1 | The amyloid cascade hypothesis, adapted from Citron
(2004). The pathogenic events shown can eventually lead to Alzheimer’s
disease (AD). The cascade starts with the generation of amyloid-β42 (Aβ42).
for presenilin proteins which are subcomponents of γ-secretase,
and ApoE-ε4, an isoform of lipoprotein which is less efficient
in catalyzing the breakdown of Aβ compared to other isoforms
(Citron et al., 1992, 1997; Schmechel et al., 1993). For example,
Down’s syndrome patients who have an extra copy of the APP
gene due to a third copy of chromosome 21, have increased Aβ
production from birth and develop classical AD pathology by
the age of 50. The earliest Aβ depositions are detected at age 12,
even before other AD lesions like neurofibrillary tangles are visible
(Lemere et al., 1996).
APP transgenic mouse models recapitulate many aspects of
the AD pathology, such as Aβ aggregation and cognitive deficits
(Ohno et al., 2004). A transgenic mouse model that is unable
to produce Aβ (i.e., BACE−/−, TG2576+ mice), shows improved
cognitive function and absence of neuronal loss in comparison
to mice that overexpress human APP-695 (i.e., Swedish familial
mutation Tg2576+) (Ohno et al., 2004; Laird et al., 2005).
In addition, very interesting is the recent finding of Jonsson
et al. (2012) of a single nucleotide polymorphism in the APP
gene near the β-cleavage site, called A673T, in which alanine
673 is substituted for threonine. This substitution reduces the
Aβ levels by approximately 40% in human cell-lines while also
protecting carriers of this mutation against AD and cognitive
decline (Jonsson et al., 2012). The A673T mutation was found to
be significantly more prevalent in the healthy control group than
the AD group. Furthermore, mutation carriers performed better
on cognitive tests than healthy non-carriers (Jonsson et al., 2012).
Another known mutation at exactly the same nucleotide which
substitutes alanine for valine (i.e., A673V), achieves the opposite
of the A673T mutation: it increases amyloid-β production and is
known to cause familial AD (Jonsson et al., 2012).
Data on the A673T mutation, the mouse models and Down
syndrome, provide evidence for the amyloid cascade hypothesis
in vivo and indicate that strategies to lower Aβ levels in the brain
are likely to be beneficial in treating AD. Logically, reducing Aβ
levels in the brain has been an approach in the development of
AD drug treatments for years.
Aβ homeostasis in the brain depends on its production, degra-
dation, efflux out of the brain and the potential formation of
insoluble aggregates. These factors can be clinically manipulated
to achieve a reduction in Aβ levels in the brain. Current tech-
nologies however are incapable in effectively manipulating the
degradation and efflux of the peptide. Inhibition of Aβ produc-
tion is a more promising option for the development of AD drug
treatment. Furthermore, by inhibiting the production of Aβ, the
Aβ peptide overload can be effectively reduced.
AMYLOID-BETA AND BETA-SECRETASE
AMYLOID-BETA BIOSYNTHESIS
Amyloid-β is produced after the cleavage of APP by two aspartic
proteases, β-secretase and γ-secretase (Ghosh et al., 2012). β-
secretase cleaves APP at the β-site and is therefore referred to
as the “β-site APP cleaving enzyme 1” (BACE1; Vassar et al.,
1999). However, β-secretase competes with α-secretase for the
APP substrate, and subsequent cleavage by α-secretase does not
generate Aβ at all. Accordingly, γ-secretase is a multiprotein
complex, containing presenilin, nicastrin, Aph1 and Pen2 and
cleaves APP at the γ-site (Wolfe et al., 1999).
Aβ biosynthesis starts when BACE1 cleaves APP at the Asp+1
residue of the Aβ-sequence, which gives rise to the N-terminus
of the novel peptide (Figure 2). This cleavage results in two
fragments, the secreted ectodomain (APPsβ) and the membrane-
bound carboxyl terminal fragment (C99). Next, C99 is cleaved
by γ-secretase, forming the C-terminus of Aβ protein and the
APP intracellular domain (AICD). This cleavage is not very
specific as most Aβ peptides that are generated by γ-secretase
activity end at amino acid 40 (Aβ40), while the remainder ends
at residue 42 (Aβ42). An excess of the latter peptide is implicated
in AD.
Evidently, γ-secretase is a suitable protease for the develop-
ment of inhibitor drugs for AD and has been actively pursued for
years (Ghosh et al., 2012). Several compounds have progressed
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FIGURE 2 | Aβ-peptide biosynthesis, adapted from Cole and Vassar (2007). APP is sequentially cleaved by BACE1 (β-secretase) and γ-secretase to
generate Aβ. Aβ formation is prevented by the activities of α-secretase, which cleaves APP to generate the secreted ectodomain, APPsα and membrane bound
fragment, C83.
to human clinical trials. However, γ-secretase has many phys-
iological functions in regulating cell growth and catabolizing
membrane proteins fragments. Subsequently, this enzyme is not
specific to APP, but also other substrates, including the trans-
membrane receptor and signaling protein Notch. Reducing Notch
activity interferes with cellular proliferation and differentiation
(Walker and Rosen, 2006). Therefore, many proposed γ-secretase
inhibitors are toxic for patients, especially if there are no other
pathways that can compensate for the loss of γ-secretase. Sev-
eral γ-secretase inhibitors however have been successful to some
extent. The drug R-flurbiprofen (FlurizanTM) for example, selec-
tively lowers Aβ42 production through allosteric modulation of
γ-secretase activity and does not inhibit the activity of Notch and
other substrates (Eriksen et al., 2003). This drug, however, was
found to have limited effect in mild AD patients and no effect in
moderate AD patients (Green et al., 2009).
This leaves another important protease in the generation of
Aβ peptide suitable for developing inhibitor drugs: β-secretase
or BACE1. Given that BACE1 is the initiating enzyme in Aβ
generation and therefore rate-limiting, it is a prime target for drug
development in AD.
BETA-SECRETASE, THE ASPARTIC PROTEASE—BACE1 AND BACE2
BACE1 is an aspartic protease, which is a family of protease
enzymes that use an aspartate residue for the catalysis of their sub-
strates. The 501 amino acid sequence of BACE1 has an N-terminal
signal sequence of 21 amino acids (amino acid 1–21), which is the
first part of the protein that exits the ribosome during translation
(Cole and Vassar, 2007). Together with the pro-peptide domain
(amino acids 22–45), the N-terminal signal sequence is removed
after translation, forming the mature aspartic protease, which
starts at amino acid Glu-46. Near its C-terminus, BACE1 contains
a single trans-membrane domain (amino acids 455–480) which
is characteristic for mammalian aspartic proteases (Dash et al.,
2003).
Furthermore, BACE1 has six luminal cysteine residues that
form three intermolecular disulfide bonds and N-linked glycosy-
lation sites (Cole and Vassar, 2007). Glycosylation is a post- and
co-translational modification in which glycans are attached to the
protease. BACE1 also contains two active site aspartate residues
in its extracellular protein domain (amino acids 93–96 and 289–
292), which are necessary for the protease activity of BACE1
(Hussain et al., 1999). This active site is perfectly positioned for
cleaving APP at the β-site.
BACE1 is not only regulated at the translational level, but
also at transcriptional level (Roßner et al., 2006). The upstream
promoter, a region of DNA that initiates transcription and is
located upstream of the transcribed gene, lacks the typical TATA
box, a general transcription factor binding site. However, there
are other transcription factor binding sites (such as for CREB and
KF-κB) that are known to influence the transcriptional activity of
the BACE1 promoter.
After transcription, the BACE1 mRNA is transported out
of the nucleus and enters the cytoplasm where it is trans-
lated. Tissue culture and animal studies indicate that BACE1
is expressed in all tissues, but mRNA levels are highest in the
pancreas and in the brain (both in brains affected and unaffected
by AD; Figure 3). The relatively high levels of BACE1 found
in the pancreas indicate a (β-secretase) function of BACE1 in
the pancreas. However, research shows that BACE1 mRNA in
the pancreas encodes a shortened splice variant that is defi-
cient in β-secretase activity (Bodendorf et al., 2001). This is
consistent with high BACE1 mRNA levels in the pancreas,
but low β-secretase activity in the organ. However, the pre-
cise function of this pancreas specific BACE1 variant remains
unknown.
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FIGURE 3 | GeneAtlas BACE1 mRNA expression pattern in human tissues, adapted from BioGPS.org [accessed on 2014-04-07]. The BACE1 mRNA is
predominantly expressed in brain tissues such as the spinal cord and hypothalamus, but also in the pancreas.
When BACE1 is transfected in APP-overexpressing cell-lines,
the protease induces an immense increase in β-secretase activity.
In comparison to control cells, the products of β-secretase cleav-
age (APPsβ and C99) are dramatically increased (Vassar et al.,
1999). Indicative of the competition between β- and α-secretase,
APPsα levels are reduced. In accordance with these findings, Aβ
peptide levels are elevated (Vassar et al., 1999). Furthermore,
when APP-overexpressing cells are exposed to BACE1 antisense
oligonucleotides, BACE1 mRNA levels are decreased and β-
secretase activity is inhibited (Vassar et al., 1999). Several other
studies indicate that BACE1 expression is increased in the brains
of AD patients when compared to healthy subjects (Fukumoto
et al., 2002; Holsinger et al., 2002).
Immediately after the discovery of BACE1, a second aspartic
protease was identified that has 64% amino acid sequence simi-
larity to BACE1 and also contains a C-terminal trans-membrane
domain. This protease has received much interest, as it is located
in the Down syndrome region of chromosome 21. Like BACE1, it
could have β-secretase activity (Saunders et al., 1999). However,
studies indicate that BACE2 is primarily expressed peripherally
and brain expression is extremely low (Bennett et al., 2000). Also,
antisense inhibition of BACE2 does not reduce Aβ generation
while overexpression of BACE2 does not result in an increased
Aβ production (Yan et al., 1999; Bennett et al., 2000). Recent
studies show that overexpression of BACE2 actually reduces Aβ
production in neurons of the mutant Tg2576 mice (i.e., mice that
overexpress APP) (Hong et al., 2002; Sun et al., 2006).
Data clearly demonstrates that BACE2 has the potential to
cleave APP within the Aβ domain, but is not involved in AD
pathogenesis. Instead, the decrease of Aβ production in APP
mutant mice under the influence of BACE2 overexpression may
indicate therapeutic interventions of BACE2 in preventing AD
pathogenesis (Sun et al., 2006).
BACE1 KNOCKOUT STUDIES
Evidently, the discussed data suggests a critical role for BACE1
in Aβ peptide generation and indicates its suitability as target
for therapeutic drug inhibition. Further research involves knock-
out (KO) models, which are important in the development of
inhibitory drugs. A natural occurring, partial BACE1 KO in
humans is the previously discussed A673T mutation in the Ice-
landic population (Jonsson et al., 2012).
The first findings by several independent groups on BACE1
KO mice models show that these animals do not produce cere-
bral Aβ peptides and amyloid deposits, and remain healthy and
fertile (Ohno et al., 2004). Swedish APP-overexpressing mice (i.e.,
Tg2576+) have highly elevated Aβ peptide levels in the brain
and develop memory deficits and plaques in later life. Crossing
Tg2576 mice with BACE1 KO mice creates a new mouse model
(i.e., BACE1−/−, Tg2576+) that do not generate Aβ, APPsβ and
C99 (Luo et al., 2001). Moreover, all products that are generated
through β-secretase activity are non-existent in these BACE1 KO
mice, even when APP is over expressed. Subsequently, several
studies were conducted to determine whether the lack of Aβ due
to BACE1 deficiency also prevents memory deficits in Tg2576
mice. BACE1−/−, Tg2576+ mice indeed do not develop memory
deficits in comparison to Aβ-overproducing mice (Kuo et al.,
1996; Ohno et al., 2004). This data unanimously demonstrates
that BACE1 is responsible for the β-secretase cleavage and no
compensatory mechanisms are present in these mice models (Cai
et al., 2001; Luo et al., 2001; Roberds et al., 2001).
However, complete elimination of BACE1 may have unin-
tended side effects similar to what was demonstrated in stud-
ies on γ-secretase inhibition (Walker and Rosen, 2006). Initial
research indicates that the absence of BACE1 does not affect
the development of embryo’s and the physiology, biochemistry,
morphology and behavior of adult KO mice. Further and more
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detailed analyses however show that complete deletion of BACE1
activity does have effects (Cole and Vassar, 2007): BACE1 KO mice
have abnormalities in both spatial and reference memories and
impairments in temporal associative memory. They do behave
normal in social recognition. These findings suggest that BACE1
not only functions in Aβ production, but also in normal memory
processing within the hippocampus (Cole and Vassar, 2007).
In addition to the memory defects found in BACE1 KO mice,
BACE1 inhibition might also cause demyelinating side effects. In
2006 it was discovered that neuregulin-1 is a BACE1 substrate
and is important for myelination early in life (Hu et al., 2006;
Willem et al., 2006). However, treatment with BACE1 inhibitors
will only take place in later life and will therefore probably not
cause demyelination. Furthermore, biochemical analysis indicate
that BACE1 processes the neuregulin-1 isoform Ig-containing β1
(IgNrg1β1; Cheret et al., 2013). Graded reduction in the IgNrg1
isoform signal strength in vivo, correlates with increasingly severe
deficits in the formation and maturation of muscle spindles,
which are critical for muscle coordination (Cheret et al., 2013).
Also, through pharmacological inhibition and mutagenesis in
animals it was found that BACE1 and Nrg1 are essential to
maintain motor coordination. Therefore, a partial inhibition of β-
secretase activity seems most beneficial. Furthermore, to evaluate
potential toxicity arising from the inhibition of BACE1, studies
need to be conducted to determine (additional) BACE1 substrates
in vivo (Vassar and Kandalepas, 2011).
BETA-SECRETASE INHIBITORS
HURDLES IN THE DEVELOPMENT OF THE FIRST BETA-SECRETASE
INHIBITORS
The previous data concerning BACE1 knockout studies, overex-
pression and antisense inhibition all support the hypothesis that
BACE1 is a prime drug target for inhibiting the production of
Aβ. The protease is critical in the biosynthesis of Aβ and found
to be elevated in the brains of AD patients (Fukumoto et al., 2002;
Holsinger et al., 2002). However, complete abolishment of BACE1
activity may result in harmful phenotypical defects in memory
processing, myelination and motor coordination.
Another hurdle that has to be overcome in the development of
a potent β-secretase inhibitor, is the blood-brain barrier (BBB).
This is the separation of circulating blood from extracellular fluid
in the central nervous system. The endothelial cells responsible
for this barrier restrict diffusion of large or hydrophilic molecules
and other objects into the brain. Passing the BBB is essential,
as BACE1 cleaves APP in the endosomes of neurons within the
brain. Therefore, a β-secretase inhibitor needs to cross the BBB
and neuronal membranes. Endothelial cells do allow the diffusion
of hydrophobic and small molecules like hormones and oxygen.
The largest molecular size that can cross the BBB is approximately
550 DA (Ghosh et al., 2012).
THE DEVELOPMENT OF BETA-SECRETASE INHIBITORS
An enzyme inhibitor is a molecule that binds to the enzyme
and thereby decreases its activity. The binding of the inhibitor
hinders the enzyme from catalyzing a reaction. The binding of an
inhibitory drug can either be irreversible or reversible. Irreversible
inhibitors covalently bond with amino acid residues that are
needed for the enzymatic activity, while reversible inhibitors bind
non-covalently to either the enzyme itself or the enzyme/substrate
complex, through hydrogen bonds, ionic bonds or hydrophobic
interactions. There are four different kinds of reversible enzyme
inhibitors (Berg et al., 2002):
• Competitive inhibition: the inhibitor has affinity for the active
site of an enzyme where the substrate also binds. This leads
the substrate and the inhibitor to compete for access to the
enzyme’s active site. Competitive inhibitors often mimic the
structure of the natural substrates. Conversely, sufficiently high
concentrations of the natural substrate, can out-compete the
inhibitor and reduce its effects.
• Uncompetitive inhibition: the inhibitor binds to the
enzyme/substrate complex, hindering the catalysis of the
natural substrate.
• Mixed inhibition: when the inhibitor binds to the enzyme, it
affects the enzyme’s binding to the substrate and vice versa.
It is possible for these inhibitors to bind at the active site,
but inhibition generally occurs from an allosteric effect where
the inhibitor binds adjacent to the active site, changing the
conformation of the enzyme. This results in reduced affinity
of the substrate for the active site.
• Non-competitive inhibition: binding of the inhibitor to the
enzyme reduces enzyme activity, but does not affect the binding
of a substrate to the active site. The concentration of the
inhibitor determines the extent of inhibition.
As previously discussed, BACE1 is a membrane bound aspar-
tic protease. Traditionally, protease inhibitors are developed by
natural product screening for lead substrates by substrate-based
methods and subsequent optimization (West and Fairlie, 1995).
Such optimization includes the replacement of hydrolyzable pep-
tide bonds by non-hydrolyzable isosteres. A peptide bond is
a chemical bond formed between two amino acids when the
carboxyl group of one reacts with the amino group of the
second amino acid. With the addition of water, this chemical
peptide bond can be cleaved in a reaction that is referred to
as hydrolysis. Isosteres are defined as functional groups that
mimic peptide bond hydrolysis, but cannot be cleaved by the
aspartic proteases (Dash et al., 2003). Furthermore, these stable
structures are thought to bind more tightly to the aspartic pro-
tease than natural substrates. Studies on the aspartic protease
inhibitor pepstatin indicates that this increased affinity is not
only due to imitation of the transition state of peptide bond
hydrolysis, but also due to the deletion of the water molecule
(hydrogen) that is bonded to the aspartate residues (Dash et al.,
2003).
Inhibitors bind to BACE1 through non-covalent interactions
and are therefore reversible inhibitors (Dash et al., 2003). Inhibi-
tion depends on BACE1 having a greater affinity for the inhibitor
than for APP, so this is a form of competitive inhibition. Maximal
inhibitor affinity is created by increasing the number of non-
covalent interactions between BACE1 and the inhibitor. Aspartic
proteases like BACE1 have a catalytic domain containing a pair
of active-site aspartic acid residues. Furthermore, BACE1 has an
elongated substrate-binding site, the subsites, that can bind up
to 11 amino acids of substrates. These substrates are processed
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with the aid of the two aspartic acid residues in the active-
site (Dash et al., 2003; Ghosh et al., 2012). Inhibitor specificity
for BACE1 can be built by taking advantage of the collective
interactions between a putative inhibitor on both sides of its
peptide bond and a part of the substrate-binding groove of
BACE1 (Dash et al., 2003). The 11 subsites have a broad amino
acid preference, but many central ones (such as P1 and P1′) prefer
hydrophobic side chains. This characteristic can be utilized in
the development of inhibitors, as good lipophilicity is important
for membrane penetration and passing the BBB (Ghosh et al.,
2012).
THE EVOLUTION OF BETA-SECRETASE INHIBITORS
The first reported BACE1 inhibitor is the P10-P4′ StatVal, devel-
oped by Elan Pharmaceuticals and it is a substrate analog that
substitutes P1-(S)-statine (Sinha et al., 1999). Shortly thereafter,
a new BACE1 inhibitor was developed and named OM99-2, an
8-residue transition analog that was designed based on substrate
specificity (Ghosh et al., 2000; Lin et al., 2000). The scissile peptide
bond of the substrate was replaced by a Leu-Alahydroxyethylene
transition-state isostere. The crystal structure of BACE1/OM99-2
complex, however, indicated that the S3′ and S4′ subsites were not
correctly formed. Despite its excellent inhibitory potency in vitro,
the peptidic structure inhibited application in vivo (Luo and Yan,
2010).
Further research into the subsite preference of BACE1 and
binding residues led to the design of a second generation of β-
secretase inhibitors: OM00-3 (Hong et al., 2002). The interactions
between the P1/P1′ subsite region of OM00-3 and the substrate
binding cleft of BACE1 are the same as for OM99-2 (Hong et al.,
2002). The multiple interactions between Arg-307 amino acid of
BACE1 and carboxylate oxygen atoms of P4 Glu amino acid of
the inhibitor, contributes to the inhibitor binding. Additionally,
leucines at P3 and P1 of OM00-3 interact with the S3 site of
BACE1 and with each other. This stabilizes the conformation of
the inhibitor.
Many substrate-based peptidomimetic inhibitors are
developed by academic research groups and pharmaceutical
companies. The problem with the BACE1 inhibitors P10-P4′,
OM99-2 and OM00-3, is that they do not have the qualified
drug properties: they are either too large in size, have a too short
half-life in vivo, are not capable of passing the BBB or have low
oral availability (Luo and Yan, 2010). Therefore, later generations
of BACE1 inhibitors are smaller and often non-peptidic.
In 2008, the pharmaceutical company CoMentis revealed that
it developed a new potent BACE1 inhibitor that passed the phase
1 clinical trial (Hey et al., 2008; Koelsch, 2008; Ghosh et al., 2012).
This small compound is named CTS-21166, can pass the BBB, has
high oral availability and is both selective and stable. CoMentis
left its structure undisclosed, but revealed that by injecting CTS-
21166 into an APP transgenic mouse (expressing both Swedish
and missense London mutations) the Aβ peptide and plaques
levels are reduced by 35% and 40% respectively (Luo and Yan,
2010). Also, the drug did not damage the myelin sheath of the
mouse model, indicating that BACE1 indeed only aids myelina-
tion during early development, as suggested previously (Willem
et al., 2006). Data from the human phase I study indicates that
CTS-21166 is safe when injected intravenously into AD patients
with doses as high as 225 mg. Results show a dose-dependent
reduction of plasma Aβ levels for an extended period of time
(Strobel, 2008). Significant inhibition of plasma Aβ persisted
beyond 72 h (Ghosh et al., 2012). Similar results were obtained
from a second phase I trial on subjects receiving an oral liquid
solution of 200 mg CTS-21166 (Ghosh et al., 2012).
The news of CTS-21166 led another pharmaceutical company,
Merck, to consider phase I testing with their BACE1 inhibitor
(Luo and Yan, 2010). In April 2012, Merck presented their phase I
data on the 64th American Academy of Neurology (ANN) annual
meeting (Forman et al., 2012). In 40 healthy adults single doses of
100 or 500 mg of their inhibitor MK-8931 reduced Aβ peptide
concentration levels in cerebral spinal fluids (CSF) up to 92%.
In the multiple dose study, CSF Aβ peptide levels dropped 50%
and 80% for 10 and 40 mg doses. The drug was well tolerated,
as no serious adverse events or study discontinuations occurred.
Furthermore, due to the 20 h half-life of MK-8931 it is ideal for
once-a-day dosing (Forman et al., 2012; Landhuis, 2012).
At the end of 2012 it was announced that Merck initiated
the Phase II/III studies of MK-8931 for the treatment of AD.
In these tests the safety and efficacy of MK-8931 versus placebo
are determined in patients with mild and moderate AD. The
global study is referred to as EPOCH and is a 78-week phase
II/III clinical trial in which doses of 12, 40 or 60 mg are tested.
The phase III trial will assess change from baseline in cognition
and function using several tests, but also AD biomarkers, such
as CSF total tau, hippocampal volume and brain amyloid. MK-
8931 is the first BACE1 inhibitor to advance to this stage of
clinical research, with 200 participants in phase II and 1800
participants in phase III. At the 11th international conference
on AD and Parkinson’s Disease that was held in the begin-
ning in March 2013 in Florence, Merck added the first data
from a trial that lasted a week in 32 mild to moderate AD
patients of the mean age of 73 years (Bowman Rogers and
Strobel, 2013; Forman et al., 2013; Dobrowolska et al., 2014).
Results indicate a decrease in CSF Aβ40 and Aβ42 of up to
84% for the 12, 40 or 60 mg doses. This indicates that that
the presence of high cerebral amyloid concentrations does not
change the pharmocodynamic and pharmacokinetic properties
of this BACE1 inhibitor. The exact working mechanisms and
molecule structures of BACE1 inhibitors MK-8931 and CTS-
21166, however, remain intellectual property and are unfortu-
nately inaccessible.
Another BACE1 inhibitor that has reached phase II trials is the
Eli Lilly’s inhibitor LY2886721. The data on phase I trial were first
presented at the Alzheimer’s Association International conference
in 2012. Daily dosing during 2 weeks, reduced BACE1 activity
by 50–75% and CSF Aβ42 by 72% (Willis et al., 2012; Bowman
Rogers and Strobel, 2013). Recently, Lilly reported that the phase
II trial of LY2886721 was terminated due to liver abnormalities
that were found in 4 out of 45 patients (Rogers, 2013). This
toxicity, however, does not have to be related to the working
mechanism of the inhibitor, but can represent off-target effects
as the livers of BACE1 knockout mice are normal.
During the Alzheimer’s Association International conference
in 2012 another BACE1 inhibitor was presented: E2609. In a
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phase I study, healthy young subjects aged 30–55 received single
doses of 5–800 mg, while healthy elderly subjects aged 65–85
received a single dose of 50 mg. Results show that E2609 was
well-tolerated across all doses, and causes prolonged reduction of
plasma Aβ of up to 45% (Lai et al., 2012, 2013). Up until now
no updates are announced on this inhibitor, but more thorough
clinical evaluation of E2609 is underway.
DISCUSSION
Research on KO, overexpression and antisense inhibition of
BACE1 show that BACE1 is the primary protease responsible for
the production of Aβ within the brains of healthy patients and
diseased patients. Especially the recent findings that the A673T
mutation in the APP gene results in a BACE1 activity reduction
and protects subjects against AD, seems very promising. Previous
efforts concerning the development of drugs based on the amyloid
cascade hypothesis, were mainly focused on another aspartic
protease, γ-secretase. BACE1, however, seems more potent as a
drug target as it is the first protease in the Aβ biosynthesis and
therefore is possibly rate limiting.
Over recent years, research groups and companies have tried
to develop the first potent BACE1 inhibitor. Due to difficulties in
developing a potent protease inhibitor, many have not reached the
clinical trials stage. Recently however, pharmaceutical company
Merck and co. announced that it developed an inhibitory drug
for the treatment of AD, named MK-8931. At the end of 2012
this drug became the first BACE1 inhibitor to reach phase II/III
of clinical human trials. The latest results from pharmaceutical
companies indicate that BACE1 inhibitors are capable of reducing
Aβ peptide levels in the brain, suggesting that they may be
effective in treating AD.
BACE1 inhibitors however still have a long way to go before
they are applicable in the battle against AD. First, extreme reduc-
tions in Aβ peptide levels through the inhibition of BACE1
may have harmful side effects. Furthermore, it was discovered
that neuregulin-1, a peptide that is essential for the normal
development of the nervous system and the heart, is also a
substrate of BACE (Britsch, 2007) and a complete abolishment
of BACE1 could affect the myelination of neurons, due to the
functioning of neuregulin-1. However, BACE1 inhibitor CTS-
21166, produced by pharmaceutical company CoMentis, did not
influence the myeline sheath in their mouse model. Apparently
BACE1 substrate neuregulin-1 only influences the myeline sheath
during early development, although it should still be taken into
account that complete inhibition of BACE1 may influence mem-
ory capacity or have other side effects. Recent research suggests
that BACE1 has more additional substrates and that it is involved
in forming connections in the brain (Kuhn et al., 2012; Zhou
et al., 2012). The study conducted by Vassar indeed indicates
that BACE1 KO mice have axon guidance defects (Rajapaksha
et al., 2011). These data however should be translated to human
data, and it is unknown how serious these defects will be.
Future studies on BACE1 substrates should evaluate the potential
toxicity of BACE1 inhibitors in vivo (Vassar and Kandalepas,
2011).
Furthermore, no single BACE1 inhibitor has currently passed
phase II/III of clinical trials and possible side effects in Alzheimer
patients and the exact clinical efficacy of the inhibitors remain
unknown. However, with the announcement that the inhibitory
drug presented by Merck and co. has reached phase II/III, new
data on possible side effects and the exact clinical efficacy are
therefore within reach. In the meantime, phase I data indicate that
there are very few and mild side effects.
In addition to the concern about possible side effects, there
remains doubt about the clinical efficacy of BACE1 inhibitors.
Results on the γ-secretase inhibitor R-flurbiprofen show that it
has limited effect in mild AD patients and no effect in moderate
AD patients (Green et al., 2009). This could also apply to BACE1
inhibitors, as both are aspartic proteases and components of a
cascade responsible for the production of the Aβ peptide. It must
be taken into account that BACE1 inhibitors prevent the produc-
tion of new Aβ peptides and plaques, but do not influence already
existing Aβ peptides. In moderate AD patients, Aβ peptides have
already substantially accumulated and many plaques are formed.
Therefore, BACE1 inhibitors are potentially better at preventing
AD instead of having a therapeutic use.
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